Welcome to our dedicated page for Acumen Pharmaceuticals SEC filings (Ticker: ABOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Acumen files periodic reports and current reports with the U.S. Securities and Exchange Commission, including Forms 10‑K, 10‑Q and 8‑K, in connection with its development of sabirnetug (ACU193), a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of early Alzheimer’s disease.
Through its 8‑K filings, Acumen reports material events such as quarterly financial results, business highlights, strategic collaboration agreements and changes in its Board of Directors. For example, recent 8‑Ks have covered the company’s financial condition, the posting of updated corporate presentations, and the appointment of a new chairman of the board. These filings complement press releases that discuss the progress of the Phase 2 ALTITUDE-AD trial, the Enhanced Brain Delivery (EBD™) collaboration with JCR Pharmaceuticals, and other corporate developments.
On this page, users can also track how Acumen describes its status as an emerging growth company, its listing of common stock on The Nasdaq Global Select Market under the symbol ABOS, and its use of collaborations and option agreements to support development of AβO-targeted therapies. While detailed insider trading information would appear in Form 4 filings and executive compensation in proxy materials, this hub focuses on the full range of EDGAR-reported documents.
Stock Titan enhances these filings with AI-powered summaries that explain key points, highlight important sections in lengthy reports such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q, and help readers quickly understand how new disclosures relate to Acumen’s Alzheimer’s disease programs and financial position.
Acumen Pharmaceuticals, Inc. has a notice of proposed sale of common stock under Rule 144. The filing covers 6,467 shares of common stock to be sold through Merrill Lynch, with an aggregate market value of $11,768.71, and lists 60,573,425 shares of common stock outstanding, all in connection with trading on NASDAQ around 01/08/2026.
The 6,467 shares were acquired on 01/06/2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan. Over the past three months, the filer, identified as James Doherty, previously sold 1,700 shares of common stock on 01/07/2026 for gross proceeds of $3,379.50.
Acumen Pharmaceuticals, Inc. insider Derek Meisner filed a notice of proposed sale under Rule 144 covering 36,911 shares of common stock through broker Merrill Lynch on or about 01/08/2026, with an aggregate market value of $67,244.23, to be sold on NASDAQ.
The shares to be sold were acquired through vesting of restricted stock unit awards granted under the issuer’s equity compensation plan on several dates in 2025 and 2026. The notice also lists prior sales during the past three months, including 4,000 shares on 01/05/2026, 10,898 shares on 01/06/2026, and 11,770 shares on 01/07/2026. Common shares outstanding were 60,573,425 as of the figure shown in the filing, which serves as a baseline for the company’s equity.
Acumen Pharmaceuticals, Inc. insider Russell Barton has filed a Form 144 notice to sell 3,530 shares of the company’s common stock through Merrill Lynch on the NASDAQ exchange. The planned sale has an aggregate market value of $6,561.55 and is against total common shares outstanding of 60,573,425.
The 3,530 shares were acquired on 01/06/2026 through the vesting of a restricted stock unit award granted under the issuer’s equity compensation plan, with payment recorded the same day. Over the prior three months, Barton sold additional Acumen common stock: 4,000 shares for $7,832.50 on 01/05/2026, 3,618 shares for $7,114.46 on 01/06/2026, and 1,700 shares for $3,378.00 on 01/07/2026.
Acumen Pharmaceuticals, Inc. insider Matt Zuga filed a Form 144 notice to sell 6,888 shares of common stock through Merrill Lynch on the NASDAQ, with an approximate sale date of 01/08/2026 and an aggregate market value of $12,513.07. These shares were acquired on 01/06/2026 via the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan.
During the past three months, Zuga has already sold additional common shares of Acumen Pharmaceuticals, Inc., including 4,000 shares on 01/05/2026 for $7,842.33, 5,100 shares on 01/06/2026 for $10,027.50, and 5,805 shares on 01/07/2026 for $11,565.85.
Acumen Pharmaceuticals, Inc. received a Form 144 notice for a planned sale of common stock. The filing covers 8,143 shares of common stock to be sold through Merrill Lynch on or about 01/08/2026 on the NASDAQ, with an aggregate market value of $14,815.32. The issuer reports 60,573,425 common shares outstanding.
The 8,143 shares were acquired on 01/07/2026 through the vesting of a restricted stock unit award granted under the company’s equity compensation plan. The seller, identified as Daniel OConnell, has also sold common stock in the past three months, including 4,649 shares on 01/05/2026, 5,102 shares on 01/06/2026, and 37,755 shares on 01/07/2026, with disclosed gross proceeds for each sale.
Acumen Pharmaceuticals, Inc. executive stock activity: CFO & Chief Business Officer Matt Zuga reported several sales of Acumen common stock. On January 5, 2026, he sold 4,000 shares at a weighted average price of $1.9606. On January 6, 2026, he sold 5,100 shares at a weighted average price of $1.9662. On January 7, 2026, he sold 4,105 shares at a weighted average price of $1.995 and an additional 1,700 shares at a weighted average price of $1.9862. Footnotes explain that the 4,000- and 1,700-share sales were automatic “sell to cover” transactions to satisfy tax withholding on vesting RSUs under Rule 10b5-1 trading plans adopted on August 30, 2024 and June 30, 2025. After these transactions, he beneficially owned 216,839 shares of Acumen common stock directly.
Acumen Pharmaceuticals Chief Medical Officer Eric Siemers reported automatic sales of company common stock to cover taxes on vesting restricted stock units. On January 5, 2026, he sold 4,000 shares at a weighted average price of $1.9587, and on January 6, 2026, he sold 6,834 shares at a weighted average price of $1.967.
The filing states these transactions were "sell to cover" sales executed under a Rule 10b5-1 trading plan adopted on September 3, 2024, to satisfy tax withholding obligations from RSU vesting. After these sales, Siemers beneficially owned 159,464 shares of Acumen Pharmaceuticals common stock in direct ownership.
Acumen Pharmaceuticals, Inc. chief executive Daniel Joseph O’Connell reported automatic sales of company common stock to cover taxes on equity awards. On January 5, 6, and 7, 2026, he sold 4,649, 5,102, and 37,755 shares of Acumen common stock, respectively, at weighted average prices of $1.971, $1.9662, and $1.986 per share. The filing states these were sell-to-cover transactions to satisfy tax withholding obligations tied to the vesting of restricted stock units under a Rule 10b5-1 trading plan adopted on June 24, 2024. Following the latest reported sale, O’Connell beneficially owned 619,982 shares of Acumen common stock directly.
Acumen Pharmaceuticals Chief Legal Officer and Corporate Secretary Derek Meisner reported several sales of common stock in early January 2026. On January 5 and 6, he sold blocks of shares, including 4,000 shares at $1.9595 and 7,097 shares at $1.9672 per share. Some of these transactions were automatic “sell to cover” sales to pay tax withholding tied to vesting restricted stock units under a Rule 10b5-1 trading plan adopted in May 2024.
Additional sales on January 6 and 7 were made under a separate Rule 10b5-1 trading plan adopted in March 2025, with prices such as $1.9670, $1.9876 and $1.9896 per share. After the reported transactions, Meisner directly beneficially owned 134,459 shares of Acumen Pharmaceuticals common stock.
Acumen Pharmaceuticals Chief Operating Officer Barton Russell reported routine insider share sales linked to equity compensation. Over January 5–7, 2026, he sold a total of 9,318 shares of Acumen common stock in three transactions at weighted average prices of
The footnotes state these were automatic “sell to cover” trades to satisfy tax withholding obligations upon vesting of restricted stock units under Rule 10b5-1 trading plans adopted on August 30, 2024 and June 25, 2025. After these sales, Russell beneficially owned 126,799 shares of Acumen common stock directly.